Golimumab as First, Second or at Least Third Biologic Agent in Patients With Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis -Post Hoc Analysis of a Non-Interventional Study in Germany
The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.